A Phase 2 interventional study of ONO-1110 and Placebo in Major Depressive Disorder (MDD, sponsored by Ono Pharmaceutical Co., Ltd.. Completed at 29 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-07-08.
Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 47 studies in Depressive Disorder, Major with a site in Japan — 3 open to participants now, 3 under way, 3 of them phase 3. Depressive Disorder, Major · Japan.
Among the 47 studies in Depressive Disorder, Major with a site in Japan, this one is the 33rd largest by enrollment of the 46 interventional ones that give a count, is one of 2 that started in 2025, is one of 12 in phase 2, and was the 44th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →3 of the 47 studies in Depressive Disorder, Major with a site in Japan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Japan, United States, Australia and 12 more countries
Ages 18–75
Eli Lilly and Company · Sites in Japan, United States, Australia and 12 more countries
Ages 18–75
Takeda · Sites in Japan
Ages 12–17
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 413 Depressive Disorder, Major studies recruiting now, 93 (23%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
47 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 15 · Phase 3 26 · Phase 4 2
First in 2006; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 103 is above the median of 79 across 2,533 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 246 across the 46 interventional studies, 147,777 across the 1 observational. Of the 44 that completed or were terminated, 33 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 47 have an industry lead sponsor. The 10 most frequent:
This study is registered under Ono Pharmaceutical Co., Ltd., one of the names counted as Ono Pharmaceutical Co. Ltd. Under that name alone:
Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.
Ono Pharmaceutical Co. Ltd has 2 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 47 studies in Depressive Disorder, Major with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To Evaluate the Efficacy and Safety of ONO-1110 in Patients with Major Depressive Disorder
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with a current or past history of psychiatric or neurological disorders that meet any of the following criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ONO-1110 · Drug: Placebo
Drug: ONO-1110 · Drug: Placebo
ONO-1110 tablets once a day
Placebo tablets once daily
Change in HAM-D17(Hamilton depression rating scale 17 items) total score from baseline to Week 8 of the treatment period
Time frame: Up to 16 weeks
The transition of HAM-D17(Hamilton depression rating scale 17 items) total score from baseline to Week 8 of the treatment period
Time frame: Up to 16 weeks
Responder rates of HAM-D17(Hamilton depression rating scale 17 items) total score at 1, 2, 4, 6, and 8 weeks of the treatment period
Responder is defined as a reduction of 50% or more in HAM-D17(Hamilton depression rating scale 17 items) total score from baseline
Time frame: Up to 16 weeks
Remitted patient rates of HAM-D17(Hamilton depression rating scale 17 items) score at 1, 2, 4, 6, and 8 weeks of the treatment period
Remitted patient is defined as a total HAM-D17(Hamilton depression rating scale 17 items) total score of 7 or less.
Time frame: Up to 16 weeks
Change in the total MADRS(Montgomery-Åsberg depression rating scale) score from baseline to Week 8 of the treatment period
Time frame: Up to 16 weeks
Transition of HAM-A(Hamilton Anxiety Scale) total score from baseline to Week 8 of the treatment period
Time frame: Up to 16 weeks
Transition of CGI-S(Clinical Global Impression of illness Severity) score from baseline to Week 8 of the treatment period
Time frame: Up to 16 weeks
Transition of QIDS-J(Quick Inventory of Depressive Symptomatology) total score from baseline to Week 8 of the treatment period
Time frame: Up to 16 weeks
Transition of CGI-I(Clinical Global Impression of Impression Important) score from baseline to Week 8 of the treatment period
Time frame: Up to 16 weeks
Plasma ONO-1110 concentrations
Time frame: Up to 16 weeks
Adverse Events
Time frame: Up to 16 weeks
Plan to share: No
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Apr 2026, 14 months.
Of 96 industry-sponsored phase 2 interventional studies under Depressive Disorder, Major, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 23. This study's 14 months is below that.
Counting every sponsor, half of 195 studies reached it within 22 months; a quarter within 14 and three quarters within 37.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: ONO-1110
Ono Pharmaceutical Co., Ltd. →